1454P Optimizing ipilimumab in RCC : Results from SAKK 07/17 (CM-980) nivolumab (N) + ipilimumab (Ipi) in mRCC

Stenner-Liewen, F.; Cathomas, R.; Rothermundt, C.a.; Beyer, J.; Mach, Nicolas; Zihler, D.; Erdmann, A.a.; Kueng, M.; Dietrich, D.; Glaus Garzon, J.; Lorch, A.; Berthold, D.r.; Läubli, H.

doi:10.1016/j.annonc.2022.07.1557

Conference presentation

English

1454P Optimizing ipilimumab in RCC : Results from SAKK 07/17 (CM-980) nivolumab (N) + ipilimumab (Ipi) in mRCC

ContributorsStenner-Liewen, F.; Cathomas, R.; Rothermundt, C.a.; Beyer, J.; Mach, Nicolas; Zihler, D.; Erdmann, A.a.; Kueng, M.; Dietrich, D.; Glaus Garzon, J.; Lorch, A.; Berthold, D.r.; Läubli, H.

Presented atESMO Congress 2022, Paris, 9-13 septembre 2022

Publication date2022-09

NotePublié dans : Annals of oncology, 2022, 33(S7) : S1209

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Immunothérapie (654)

Citation (ISO format)

STENNER-LIEWEN, F. et al. 1454P Optimizing ipilimumab in RCC : Results from SAKK 07/17 (CM-980) nivolumab (N) + ipilimumab (Ipi) in mRCC. In: ESMO Congress 2022. Paris. 2022. doi: 10.1016/j.annonc.2022.07.1557

Presentation

OA OTHER

Identifiers

PID : unige:176126
DOI : 10.1016/j.annonc.2022.07.1557

Additional URL for this publicationhttps://linkinghub.elsevier.com/retrieve/pii/S0923753422034081

89views

73downloads

Creation06/12/2023 14:00:19

First validation03/04/2024 08:55:04

Update08/10/2024 15:14:37

Status update08/10/2024 15:14:37

Last indexation01/11/2024 09:07:14

Archive ouverte UNIGE

1454P Optimizing ipilimumab in RCC : Results from SAKK 07/17 (CM-980) nivolumab (N) + ipilimumab (Ipi) in mRCC

Technical informations